Navigation Links
Regado Biosciences' REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
Date:5/14/2008

in a prestigious, clinically oriented, peer-reviewed publication."

Results from Regado's 1c study were presented previously at the American Heart Association's 2007 Scientific Sessions.

About REG1 Anticoagulation System Clinical Program

In the Phase 1c clinical study, the researchers randomized 39 healthy volunteers to receive either three consecutive REG1 treatment cycles or placebo. Each REG1 cycle consisted of an intravenous (IV) bolus of RB006 dosed at 0.75 mg/kg, followed an hour later by a descending dose of RB007, ranging from a 2:1 to 0.125:1 antidote:drug ratio (1.5 mg/kg to 0.094 mg/kg of RB007). Clinical and coagulation assessments were measured for 14 days.

The Phase 1 program included two additional studies. A Phase 1a study enrolled 84 healthy volunteers, while a Phase 1b study enrolled 50 patients with stable coronary artery disease who were receiving aspirin with or without clopidogrel. The results showed an IV bolus injection of RB006 achieved, in both study populations, a prompt, consistent, and dose-dependent prolongation of activated partial thromboplastin time (aPTT). In addition, a 1 mg/kg dose of RB006 resulted in essentially complete Factor IXa inhibition. The studies also demonstrated an IV bolus injection of RB007 administered in a 2:1 antidote:drug ratio successfully reversed prolonged aPTT within a median of one minute, with no rebound increase up to seven days. Despite dual antiplatelet use in 19 subjects, there were no major bleeding or other serious adverse events observed in either study.

Based upon the combined results of the Company's Phase 1a, 1b, and 1c studies, Regado initiated REVERSAL-PCI, a multi-center, open-label, randomized Phase 2a clinical study of the REG1 anticoagulation system. The Phase 2a study is enrolling 26 patients undergoing elective percutaneous coronary intervention (PCI) to assess whether REG1 can replace standard heparin therapy during the performance of coronary balloon an
'/>"/>

SOURCE Regado Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
2. Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
3. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING
4. Pressure BioSciences, Inc. to Discuss First Quarter 2008 Financial Results and Provide Business Update
5. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
6. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
8. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
9. Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference
10. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
11. Raven biotechnologies Announces Collaboration With Monogram Biosciences to Advance Diagnostic Cancer Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are currently ... seniors will die with Alzheimer’s or another dementia, according ... shocked many Americans into looking for ways to improve ... age-related cognitive disorders. Jonathan Weisman, president of Biohack Pure, ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
(Date:1/14/2014)... Md. , Jan. 14, 2014  Organovo announced today ... the National Institutes of Health (NIH) to help scientists ... treatments to patients on a faster timeline. Organovo is ... (NCATS) and the National Eye Institute (NEI) to develop ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... at the U.S. Department of Energy (DOE) Joint Genome Institute ... analysis of the complete genome of sorghum, a major food ... The genome data will aid scientists in optimizing sorghum ... but also for biofuels production. The comparative analysis of ...
... RICHMOND, Calif., Jan. 28 Sangamo BioSciences, Inc. (Nasdaq: ... will release its fourth quarter and year-end 2008 financial ... closes. The press release will be followed by a ... open to the public via telephone and webcast. During ...
... Inc. (OTCBB: JMAR), a leading innovator in the ... detection of chemical, biological, radiological, nuclear and explosive ... detection expert John A. Adams, Ph.D. will be ... Chemistry (IFPAC) annual meeting on Wednesday, January 28, ...
Cached Biology Technology:Scientists publish complete genetic blueprint of key biofuels crop 2Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast 2Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast 3JMAR Technologies' Chief Scientist Invited by Pfizer Inc. to Speak at IFPAC -- BioSentry Makes Strides in Pharma Market 2JMAR Technologies' Chief Scientist Invited by Pfizer Inc. to Speak at IFPAC -- BioSentry Makes Strides in Pharma Market 3JMAR Technologies' Chief Scientist Invited by Pfizer Inc. to Speak at IFPAC -- BioSentry Makes Strides in Pharma Market 4
(Date:4/20/2014)... the body,s master cells demonstrate a bizarre property ... a study published today from scientists at the University ... is one which may have application as wide-ranging as ... stretched will contract. For example, if one pulls on ... The opposite is also true: squeeze a material and ...
(Date:4/20/2014)... Lincoln, Neb., April 20, 2014 -- Using corn crop ... carbon and can generate more greenhouse gases than gasoline, ... Nature Climate Change . , The findings by ... on whether corn residue can be used to meet ... greenhouse gas emissions. , Corn stover -- the stalks, ...
(Date:4/18/2014)... a twist to the story of how barnyard chickens came ... in the journal Proceedings of the National Academy of ... that lived 200-2300 years ago in Europe, researchers report that ... looked far different from the chickens we know today. , ... with modern domestic chickens -- such as their yellowish skin ...
Breaking Biology News(10 mins):Bulletproof nuclei? Stem cells exhibit unusual absorption property 2Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Ancient DNA offers clues to how barnyard chickens came to be 2
... and its far reaching impacts will be discussed in New ... signs of climate change in their own countries -- Iceland ... can their countries serve as models for the rest of ... domestic and global climate change on Monday, Nov. 5 at ...
... an affiliate of Harvard Medical School, have discovered a ... other eye disease to keep track of changes in ... weeks PLoS ONE (October 24, 2007) they demonstrate that ... after-effect (TAE) can accurately identify the location and breadth ...
... at the Albert Einstein College of Medicine have been ... Drs. Thomas Rohan, Susan Horwitz and Rachel Hazan each ... to support the advancement of breast cancer research. At ... which is to achieve prevention and a cure for ...
Cached Biology News:Presidents of Iceland, Bangladesh to discuss global climate change in New Orleans 2 'Twinkle after-effect' can help retinal patients detect vision loss quickly and cheaply 2 'Twinkle after-effect' can help retinal patients detect vision loss quickly and cheaply 3Einstein researchers receive grants totaling $700,000 for innovative breast cancer research 2
Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
Mouse monoclonal antibody raised against a partial recombinant CHD8. NCBI Entrez Gene ID = CHD8...
... Mouse monoclonal antibody raised against ... Immunogen: TOPORS ... a.a) partial recombinant protein with ... Accession Number: NM_005802 ...
Biology Products: